Recon: FDA adds warnings on Abbvie, Lilly and Pfizer JAK drugs; EMA recommends Roche arthritis drug for severe COVID

• Biden’s free at-home test promise could come with added costs (Politico)
• Pfizer could have vaccine data for kids under age 5 by year-end, CEO says (NBC)
• Merck takes aim at Pfizer’s Covid pill as concerns linger over its own drug (FT)
• Documents reveal the secrecy of America's drug pricing matrix (Axios)
• Johnson & Johnson Prepares to Untangle Finances Ahead of Planned Split (WSJ)
• FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly (Reuters)

• UK’s BenevolentAI agrees Europe’s largest Spac deal (FT) (Fierce)
• WHO advises against use of convalescent plasma for covid-9 (WHO)
• EU regulator backs Roche's arthritis drug for treating severe COVID-19 (Reuters)
• Pfizer and Merck Covid-19 Pills Are Coming Soon in the U.S., but Other Countries Will Have to Wait (WSJ)
• AstraZeneca blocks take-private buyout of Sobi (PMLive)
• AstraZeneca Studies Listing of New Vaccines Division (Bloomberg) (Fierce)
• Novartis working on pan-coronavirus oral treatment, CEO says (Reuters)
• COVID shots are finally arriving, but Africa can't get them all into arms (Reuters)
• South Africa's Biovac to start making Pfizer-BioNTech COVID-19 vaccine in early 2022 – exec (Reuters)

• Next pandemic could be more lethal than COVID, vaccine creator says (Reuters)
• Merck ties up with Thermo Fisher to make its COVID-19 pill in Canada (Reuters)
• Fauci says booster shots likely give cross protection against ‘wide range’ of Covid variants (CNBC)
• Is It Time to Change the Definition of ‘Fully Vaccinated’? (KHN)
• A J.&J. booster works well for people who had Pfizer-BioNTech doses originally, a study finds. (NYTimes)
• ‘Wall of secrecy’ in Pfizer contracts as company accused of profiteering (The Guardian)
• Vials of Remdesivir recalled due to glass contamination (The Hill)
• Russia has sent documents to India for Sputnik M registration, says RDIF (Reuters)
• Omicron spreads in India, full vaccination in focus (Reuters)
• Roche launches 3 omicron variant research tests days after TIB Molbiol buy (Fierce)
• Thermo Fisher, Verily on FDA list of COVID-19 tests affected by omicron variant (MedtechDive)

• Novartis petitions FDA to block 18 generic competitors for its megablockbuster heart drug until 2024 (Endpoints)
• Pfizer, Amgen and Janssen seek further clarity on FDA's new benefit-risk guidance (Endpoints)
• FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma (FDA)
• The 2022 wave coming? Top analyst says Big Pharma will have more than $1T available to satisfy its growing appetite for biotech M&A (Endpoints)
• Stoke Therapeutics drug, targeting genetic cause of childhood epilepsy, reduces seizure activity (STAT)
• Biohaven's migraine therapy shows rapid pain relief in late-stage study (Reuters) (BioPharmaDive)
• FDA slams Reata's kidney drug as ineffective ahead of adcomm meeting (Endpoints)
• Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal (Endpoints)
• Bolt Bio goes bust as investors boo single response in early test against HER2-expressing tumors (Endpoints)
• Even as boom wanes, a new $200M SPAC is still hoping for another big score (Endpoints)

• BD finalizes name and leadership for its billion-dollar diabetes spinoff (Fierce)
• RefleXion snags FDA breakthrough status for cancer-guided radiotherapy to treat lung tumors (Fierce)

• Congress passes on delay to Medicare rate cuts for lab tests, for now (MedtechDive)
• Zoll Medical Escapes Liability For Alleged Defibrillator Defect (Law360)
• Mallinckrodt Escapes $320M Acthar Antitrust Claim In Ch. 11 (Law360)